Published in Mol Ther on September 22, 2006
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol (2008) 3.01
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Intelligent design: combination therapy with oncolytic viruses. Mol Ther (2009) 1.68
Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther (2008) 1.67
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Clin Cancer Res (2015) 1.52
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther (2009) 1.35
In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals. Sensors (Basel) (2010) 1.33
Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res (2014) 1.23
Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther (2009) 1.13
Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev (2009) 1.10
Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther (2011) 1.04
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol (2012) 1.03
E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther (2007) 1.02
The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host. Gene Ther (2010) 1.02
A potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasis. Clin Cancer Res (2009) 1.02
The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity. PLoS One (2014) 0.98
Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther (2012) 0.96
Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia (2013) 0.96
The status of gene therapy for brain tumors. Expert Opin Biol Ther (2007) 0.95
Adenoviral virotherapy for malignant brain tumors. Expert Opin Biol Ther (2009) 0.88
Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells. Adv Virol (2011) 0.85
Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. BMC Cancer (2011) 0.84
Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging. Clin Cancer Res (2011) 0.84
Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters. Cancer Gene Ther (2014) 0.82
Temporal and spatial distribution of murine placental and brain GLUT3-luciferase transgene as a readout of in vivo transcription. Am J Physiol Endocrinol Metab (2012) 0.81
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No? J Cancer (2015) 0.81
Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus. J Virol (2013) 0.79
Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs. Mol Ther Nucleic Acids (2013) 0.78
Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma. World J Gastroenterol (2008) 0.78
Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma. Viruses (2014) 0.78
Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps. J Transl Med (2015) 0.77
In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells. Gene Ther (2015) 0.77
Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses. Hum Gene Ther (2014) 0.75
The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8(+)T Cell Anti-tumor Activity. Mol Ther Oncolytics (2017) 0.75
The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications. Oncolytic Virother (2015) 0.75
Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol (1995) 5.75
Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci U S A (1991) 4.07
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3.64
Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol (2004) 3.36
Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia (2001) 2.97
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet (1993) 2.53
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J Virol (2002) 2.31
A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther (1998) 2.14
Oncolytic viruses. Nat Rev Cancer (2002) 2.10
Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther (2001) 1.96
Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet (1993) 1.95
In vivo tracking of neural progenitor cell migration to glioblastomas. Hum Gene Ther (2003) 1.89
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86
Luciferase imaging of a neurotropic viral infection in intact animals. J Virol (2003) 1.83
Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther (2001) 1.55
Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 1.54
Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther (2004) 1.51
Imaging transgene expression in live animals. Mol Ther (2001) 1.43
Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther (2003) 1.35
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res (2002) 1.30
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res (2001) 1.24
A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther (2004) 1.23
Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res (2002) 1.18
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res (1994) 1.15
Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res (2004) 1.10
A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res (2001) 1.08
Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res (2004) 1.08
Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res (2005) 1.07
Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences. Gene Ther (2003) 1.05
Bioluminescence imaging in vivo - application to cancer research. Expert Opin Biol Ther (2003) 1.03
The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther (2002) 1.00
Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors. Cancer Res (2002) 0.98
Cytotoxic cells in immunodeficient athymic mice. Immunopharmacol Immunotoxicol (1994) 0.96
Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res (2001) 0.95
Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res (2001) 0.95
Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther (2005) 0.94
ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res (2000) 0.94
Noninvasive imaging of transcriptionally restricted transgene expression following intratumoral injection of an adenovirus in which the COX-2 promoter drives a reporter gene. Mol Imaging Biol (2004) 0.91
Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes (2001) 0.90
Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res (2004) 0.89
In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther (2003) 0.88
Noninvasive of adenovirus tumor retargeting in living subjects by a soluble adenovirus receptor-epidermal growth factor (sCAR-EGF) fusion protein. Mol Imaging Biol (2004) 0.88
Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol (1998) 0.87
Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. J Gene Med (2005) 0.82
The potential impact of hypoxia on the success of oncolytic virotherapy. Curr Opin Mol Ther (2005) 0.82
Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24. Gene Ther (2005) 0.81
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med (2007) 11.51
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol (2005) 9.57
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med (2003) 9.09
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol (2002) 6.06
Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther (2005) 6.04
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Fluorescence molecular tomography resolves protease activity in vivo. Nat Med (2002) 5.53
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Arthritis critically dependent on innate immune system players. Immunity (2002) 5.31
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell (2010) 5.11
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res (2008) 4.81
Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res (2008) 4.64
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Negative regulation of the deacetylase SIRT1 by DBC1. Nature (2008) 4.29
Chip-NMR biosensor for detection and molecular analysis of cells. Nat Med (2008) 4.29
Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation (2007) 4.20
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol (2002) 4.13
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
Tetrazine-based cycloadditions: application to pretargeted live cell imaging. Bioconjug Chem (2008) 3.93
Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity (2006) 3.92
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2007) 3.85
Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans-cyclooctene cycloaddition. Angew Chem Int Ed Engl (2009) 3.63
Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation (2006) 3.57
Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation (2007) 3.51
Molecular imaging in drug discovery and development. Nat Rev Drug Discov (2003) 3.44
Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA (2011) 3.40
Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol (2005) 3.40
Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A (2006) 3.38
Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev (2008) 3.34
A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods (2008) 3.31
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Intravital imaging. Cell (2011) 3.18
Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet (2012) 3.14
Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics (2007) 3.09
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 3.06
Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med (2012) 2.92
Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem (2006) 2.91
MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res (2007) 2.90
Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol (2010) 2.90
Near-infrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol (2009) 2.89
An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater (2006) 2.84
Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector. Sci Transl Med (2012) 2.82
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell (2012) 2.78
Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct. Circ Res (2007) 2.77
Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A (2004) 2.77
Rapid detection and profiling of cancer cells in fine-needle aspirates. Proc Natl Acad Sci U S A (2009) 2.75
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
Complete reconstitution of a highly reducing iterative polyketide synthase. Science (2009) 2.68
Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res (2005) 2.67
Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology (2002) 2.64
In vivo imaging of proteolytic activity in atherosclerosis. Circulation (2002) 2.62
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell (2010) 2.59
Molecular imaging in the clinical arena. JAMA (2005) 2.59
Image-based genome-wide siRNA screen identifies selective autophagy factors. Nature (2011) 2.58
A submillimeter resolution fluorescence molecular imaging system for small animal imaging. Med Phys (2003) 2.58
Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg (2006) 2.58
miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell (2008) 2.57
Bioorthogonal turn-on probes for imaging small molecules inside living cells. Angew Chem Int Ed Engl (2010) 2.57
Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation (2006) 2.56
A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res (2003) 2.55
Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation (2008) 2.52
Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. Nat Nanotechnol (2010) 2.49
One-Pot Synthesis of New Symmetric and Asymmetric Xanthene Dyes. Tetrahedron Lett (2007) 2.49
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A (2009) 2.47
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst (2007) 2.46
Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation (2005) 2.45
Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem (2002) 2.45
Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation (2011) 2.45
Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A (2012) 2.42
Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res (2006) 2.42
PET/MRI of inflammation in myocardial infarction. J Am Coll Cardiol (2012) 2.39
Identification of the target self-antigens in reperfusion injury. J Exp Med (2006) 2.38
Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol (2009) 2.35
Molecular imaging of cardiovascular disease. Circulation (2007) 2.33
Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol (2009) 2.33
The Gs-linked receptor GPR3 maintains meiotic arrest in mammalian oocytes. Science (2004) 2.32
Tembusu virus in ducks, china. Emerg Infect Dis (2011) 2.30
Colonic adenocarcinomas: near-infrared microcatheter imaging of smart probes for early detection--study in mice. Radiology (2007) 2.29
PepBank--a database of peptides based on sequence text mining and public peptide data sources. BMC Bioinformatics (2007) 2.27
Quantitative real-time catheter-based fluorescence molecular imaging in mice. Radiology (2007) 2.26